(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
New studies of old dogs help scientists understand where they came from - 2Geomagnetic storm grounds launch of Mars space weather satellites
- 3Africa's energy giants eye long-term gains on Iran war disruption
- 4Doritos and Cheetos debut 'NKD' options, without artificial colors or flavors
- 5Slovakia rejects EU call to scrap higher fuel prices for foreign cars
- IDF destroys Hezbollah rocket launcher used in large rocket salvo towards Haifa, Galilee
- 4 Creative Savvy Home Gadgets of 2024: Reforming Home Robotization and Security
- The Eastern Bongo, Kenya’s Rare Forest Antelope on the Brink
- Al-Sharaa denies he called for 80% of Syrians to return from Germany
- Father and son spending Christmas together after health scares
- Coalition led by Iraqi PM al-Sudani wins parliamentary elections
- German politician urges more face-to-face interaction in digital age
- 4 Masked Men Steal Renoir, Matisse and Cézanne Paintings Worth Over $10 Million in 3-Minute Heist
- Will your baby get a hep B vaccine? What RFK panel's ruling means.
